LILRB1 and neoplasm: Pre-clinical in vivo and ex vivo data for an anti-LILRB1 blocking antibody (BND-22) demonstrated a shift in the tumor microenvironment towards a more pro-inflammatory state, which translated into tumor suppression seen in different in vivo models including lung, colon and H&N cancer [34].